Case 22

Published on 03/03/2015 by admin

Filed under Neurology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1429 times

Case 22

HISTORY AND PHYSICAL EXAMINATION

A 60-year-old woman presented with a 5- to 10-year history of leg weakness and a sense of unsteadiness of insidious onset. Recently, she had become aware of mild impairment of sensation over the tips of the fingers and toes. She had mild low back pain with no radicular pain. For many years before this, she had aching discomfort in both feet, which worsened with activity and weight bearing.

Her medical history was benign, except for hypertension and chronic anxiety disorder. Her medications included alprazolam (Xanax®) and diltiazem (Cardizem®). Family history was relevant for a 30-year-old son with hammer toes, high-arched feet, and “thin legs” since childhood. She had a daughter and a maternal cousin with high-arched feet. Parents were deceased, with no definite history of neuromuscular disease.

The general examination was relevant for bilateral pes cavus deformities without hammer toes. There were no skin trophic changes. On neurologic examination, the fundi were normal without retinal pigmentary changes. Cranial nerves were normal. There was atrophy of all intrinsic muscles of both hands. Distal legs were thin with inverted-champagne bottle appearance. She could not wiggle her toes. Manual muscle examination revealed bilateral symmetrical weakness, worse distally. Toe flexors and extensors were 0/5 (Medical Research Council [MRC]), ankle dorsiflexors and plantar flexors were 4-/5, and hand intrinsics 4+/5. Deep tendon reflexes were +1 in the upper extremities but absent in the legs. Sensation revealed decreased position and vibration sense at the toes, and to a lesser extent at the ankles. Pin and touch sensation was relatively decreased in all four extremities, symmetrically worse distally with a stocking-and-glove distribution. Gait was steppage due to foot weakness. She could not walk on heels or toes. Romberg test was negative.

An electrodiagnostic (EDX) examination was performed.

Please now review the Nerve Conduction Studies and Needle EMG tables.

EDX FINDINGS AND INTERPRETATION OF DATA

Relevant EDX findings in this case include:

3. Marked slowing of motor distal latencies, conduction velocities, and F wave latencies in the upper extremities, along with moderate reduction of distal CMAP amplitudes (Figure C22-1). Distal latencies are 200 to 300% of the upper limit of normal values, conduction velocities are 45 to 50% of the lower limit of normal, and F wave latencies are 154 to 168% of the upper limit of normal values.

These findings are compatible with a chronic, demyelinating, sensorimotor peripheral polyneuropathy. Uniform and symmetrical slowing of motor conduction studies and the absence of conduction blocks are more consistent with an inherited, rather than an acquired, demyelinating polyneuropathy.

Based on the clinical manifestations, family history, and EDX findings, this case is consistent with an inherited demyelinating, sensorimotor peripheral polyneuropathy, as is seen with autosomal dominant hereditary motor sensory neuropathy (HMSN) type I (Charcot-Marie-Tooth disease type I).

DISCUSSION

Classification

Hereditary neuropathies are a heterogeneous group of peripheral nerve disorders (Figure C22-2). Some have a known metabolic basis and potential therapies (Table C22-1). The hereditary neuropathies that are not based on known specific metabolic defect are classified into three clinical groups: (1) hereditary motor and sensory neuropathies (HMSNs); (2) hereditary sensory and autonomic neuropathies (HSANs); and (3) hereditary motor neuropathies (HMNs).

image

Figure C22-2 Classification of hereditary neuropathies.

(Adapted, with revisions, from Thomas PK. Classification and electrodiagnosis of hereditary neuropathies. In: Brown WF, Bolton CF, eds. Clinical electromyography, 2nd ed. Boston, MA: Butterworth-Heinemann, 1993, pp. 391–425.)

The hereditary motor and sensory neuropathies (HMSNs) were classified by Dyck and Lambert into three predominant types (1) HMSN I, a demyelinating type; (2) HMSN II, a neuronal (axonal) type; and (3) HMSN III (Dejerine-Sottas disease), a severe demyelinating neuropathy of infancy and early childhood. HMSN I and II are characterized by skeletal deformities (pes cavus, hammer toes, scoliosis), insidious onset of distal lower more than upper extremities weakness, atrophy and sensory loss, and reduced or absent deep tendon reflexes. Based on clinical examination, these disorders are difficult to distinguish from each other because of similar phenotypes. With the recent influence of chromosomal linkage and gene identification, the term Charcot-Marie-Tooth disease (CMT) reemerged which created some confusion in the nomenclature and classifications of these disorders.

Charcot-Marie-Tooth disease (CMT) is subdivided into six major types with some but not perfect correlation to the HMSN classification (Table C22-2). CMT1 and CMT2 are interchangeable with HMSN I and HMSN II. The name Dejerine-Sottas syndrome (DSS, Dejerine-Sottas disease) is preserved and is the same condition as HMSN III. The term CMT3 is not commonly used since the genes involved with DSS are the same as CMT1. CMT4 is a new designation for a group of autosomal recessive CMT and should not be confused with HMSN IV which is Refsum disease. CMTX is an X-linked disorder and hereditary neuropathy with liability to pressure palsy (HNPP) is a distinct disorder characterized by recurrent mononeuropathies.

Table C22-2 Charcot-Marie-Tooth Disease (CMT, Hereditary Motor and Sensory Neuropathy, HMSN) Subtypes, Its Variants and Their Genetic Causes

Disorder Locus/Gene Protein
Charcot-Marie-Tooth Disease Type 1 (CMT1, HMSN I, Autosomal-Dominant, Demyelinating)
CMT1A 17p11.2-12/PMP22* Peripheral myelin protein 22
CMT1B 1q22-23/MPZ Myelin protein zero
CMT1C 16p13.1-12.3/LITAF SIMPLE
CMT1D 10q21.1-22.1/EGR2 Early growth response protein 2
Charcot-Marie-Tooth Disease Type 2 (CMT2, HMSN II, Autosomal-Dominant, Axonal)
CMT2A 1p35-36/KFI1B Kinesin-like protein Mitousin 2
CMT2B 3q13-22/RAB7 Ras-related protein
CMT2C 12q23-24/? ? (unknown)
CMT2D 7p15/GARS Glycy-tRNA synthetase
CMT2E 8P21/NEFL Neurofilament triplet L protein
CMT2F 7q11-21/HSP27 Small heat shock protein
CMT2 1q22/MPZ Myelin protein zero
Dejerine-Sottas Syndrome (DSS, HMSN III, CMT3, Autosomal-Dominant or Recessive, Demyelinating)
DSS A 17p/PMP22 Peripheral myelin protein 22
DSS B 1q/MPZ Myelin protein zero
DSS C 10q/EGR2 Early growth response protein 2
DSS D 8q23 Unknown
Charcot-Marie-Tooth Disease Type 4 (CMT4, Autosomal-Recessive, Axonal or Demyelinating)
CMT4A 8q13-21/GDAP1 Ganglioside-induced differentiation-associated protein-1
CMT4B1 11q22/MTMR2 Myotubularin-related protein-2
CMT4B2 11p15/MTMR13 Myotubularin-related protein-13
CMT4C 5q23-33/KIAA1985
CMT4D 8q24.3/NDRG1 N-myc downstream-regulated gene-1
CMT4E 10q21.1-22.1/EGR2 Early growth response protein 2
CMT4F 19q13.1-13.2/PRX Periaxin gene
X-linked Charcot-Marie-Tooth Disease (CMTX, Axonal or Demyelinating)
CMTX (X-linked) Xq13-q21/CX32(GJB1) Connexin 32 (gap junction protein-β-1)
Hereditary Neuropathy with Liability to Pressure Palsy (HNPP, Demyelinating)
HNPP (autosomal dominant) 17p11.22/PMP22 Peripheral myelin protein 22

* Duplication (98%) and point mutation (2%).

Deletion (80%) and point mutation (20%).

The hereditary sensory and autonomic neuropathies (HSANs) are very rare and familial neuropathies with selective involvement of the primary sensory, with or without the autonomic, fibers. They should be distinguished from inherited disorders that affect large primary afferent neurons (spinocerebellar degeneration). They are currently subdivided into five types, based on mode of inheritance, natural history, electrophysiologic characteristics and histopatologic findings (Table C22-3).

Table C22-3 Hereditary Sensory and Autonomic Neuropathy (HSAN)

Disorder Locus/Gene Protein
HSAN I (hereditary sensory radicular neuropathy) 9q22.1-q22.3/SPTLC1 Serine-palitoyltransferase-1
HSAN II (congenital sensory neuropathy) 12p13-33
HSAN III (familial dysautonomia, Riley-Day syndrome) 9q31-33/IKBKAP Inhibitor of kappaB-kinase complex associated polypeptide
HSAN IV (congenital sensory neuropathy with anhidrosis) 1q21-22/TRKA
HSAN V 1q21-22/NTRK1

The hereditary motor neuropathies (HMNs) are loosely subdivided into proximal and distal (Table C22-4). The proximal HMNs are better known as spinal muscular atrophies (SMAs). These are among the most common autosomal recessive disorders in childhood affecting 1/10 000 live births with carrier frequency of 1/50. Spinal muscular atrophy is caused by a deficiency of the ubiquitous survival motor neuron (SMN) protein, which is encoded by the SMN genes, SMN1 and SMN2, on chromosome 5q. The distal HMNs are a genetically and clinically heterogeneous group of disorders that are also known as spinal CMT because of their overlap with CMT. They are characterized by distal weakness with or without foot deformities, but without sensory or autonomic involvement. Sensory nerve action potentials are normal while the motor NCSs reveal low-amplitude CMAPs with normal or borderline velocities, consistent with motor axonopathy. The inheritance of HMNs is either dominant or recessive. Only few have been mapped to a chromosome or have a defined gene mutation.

Table C22-4 Hereditary Motor Neuropathy (HMN)

Proximal HMN (Spinal Muscular Atrophy, SMA, Autosomal-Recessive, Mutations of the Survival Motor Neuron 1 (SMN 1) Gene on Chromosome 5q13)
SMA I Werdnig-Hoffmann disease. Onset before the age of 6 months, inability to sit or walk, and fatal before the age of 2 years
SMA II Intermediate, arrested Werdnig-Hoffmann disease. Onset between 6 and 18 months of age, able to sit but not walk and survive beyond the age of 4 years
SMA III Kugelberg-Welander disease
SMA IIIa Onset between the age of 2 to 3 years, survive into adulthood and able to walk independently usually until age 20–40 years
SMA IIIb Onset after the age of 3 years and able to walk independently till age 30–50 years
SMA IV Adult SMA. Variable age of onset, but rarely before the age of 20 years and usually after the age of 30 years
Bulbospinal (Kennedy Disease, X-Linked CAG Repeat Expansion of the Androgen Receptor Gene on Chromosome Xq13.1) Distal HMN (Spinal Form of Charcot-Marie-Tooth Disease)
HMN I Juvenile onset, autosomal dominant
HMN II Adult onset, autosomal dominant (12q24)
HMN III Mild juvenile, autosomal recessive (11q13)
HMN IV Severe juvenile, autosomal recessive
HMN V Upper limb predominance, autosomal dominant (7p)
HMN VI Severe infantile with respiratory distress, autosomal recessive
HMN VII Vocal cord paralysis, autosomal dominant (9p21.1-p12)
Scapuloperoneal
Type I Autosomal dominant
Type II Autosomal recessive
Bulbar
Type I Autosomal recessive (Vialetto-Van Laere syndrome)
Type II Autosomal recessive (Fazio-Londe disease)

Clinical Features and Genetics

Electrodiagnostic studies have proven to be the most important distinguishing test. CMT1, is also known as HMSN I or the demyelinating form of CMT, is a predominantly demyelinating polyneuropathy that is characterized by prominent uniform slowing of motor conduction velocities, with relative preservation of CMAP amplitudes. CMT2, also known as HMSN II or the neuronal form of CMT, is a predominantly axonal polyneuropathy that can be distinguished by normal or near-normal motor distal latencies and conduction velocities and decreased CMAP amplitudes. CMTX is an X-linked disorder characterized by intermediate slowing of conduction velocities, placing this disorder in the midst between CMT1 and CMT2.

Charcot-Marie-Tooth Disease 1 (CMT1, HMSN I)

Hereditary motor and sensory neuropathy I (HMSN I, CMT1) is the prototype of all inherited neuropathies. It is an autosomal-dominant disorder with complete penetrance and with a marked interfamily and intrafamily clinical phenotypic variability. The age of symptom onset varies from birth through the forties. Many adult patients can trace, in retrospect, their symptoms before the age of 20. These childhood or adolescence manifestations may include incoordination, frequent ankle or foot trauma, or poor athletic ability. The disorder is a slowly progressive, distal, symmetrical, motor more than sensory, peripheral polyneuropathy. The most common presenting symptoms are related to muscle weakness, muscle atrophy, or foot deformity (pes cavus, hammer toes, pes equinovarus, or pes planus). Many patients undergo surgical correction of foot deformity before correct diagnosis. Sometimes, the diagnosis is made during EDX studies for other, unrelated symptoms, or it may occur as part of an evaluation of family members. There is poor correlation in CMT1 between the clinical findings and conduction velocities.

Common findings on examination include distal muscle weakness, atrophy, distal areflexia, pes cavus, and hammer toes (Figure C22-3). The atrophy is predominant in the foot but may extend into the distal legs, resulting in an “inverted champagne bottle” appearance to the leg, and into the hands, resulting in “claw hands.” Although most patients do not complain of positive sensory symptoms, there is distal loss of all sensory modalities. Pain, other than that related to foot deformity and callus formation, is rare. Scoliosis is present in a minority of patients. Enlarged and palpable peripheral nerves may be identified in some patients with HMSN I. Late in the disease, steppage gait and claw hands are common. Although the disorder is frequently disabling, the life expectancy of patients with the disease is normal.

Molecular and genetic studies have further subdivided CMT1 into four subtypes, with no definitive phenotypic characteristics that could accurately distinguish among them. These are named 1A, 1B, 1C, and 1D (see Table C22-2). CMT1A is the most common inherited neuropathy. Most patients have a tandem duplication of a 1.5 Mb region, which contains the peripheral myelin protein-22 (PMP22) gene, on chromosome 17p11.2p12. Duplication of PMP22 gene leads to overexpression (increased dosage) of the peripheral myelin protein. Occasional patients have point mutations of the PMP22 gene complex. CMT1B is associated with mutations of the myelin protein zero (MPZ) gene located on chromosome 1q22-23. The exact function of PMP22 and MPZ is not well understood, but both proteins are integral parts that likely play a major role in myelin compaction. CMT1C and CMT1D have been mapped to chromosome 16p and 10q with gene loci, named LITAF and EGR2, respectively.

Charcot-Marie-Tooth Disease 4 (CMT4)

Autosomal-recessive forms of hereditary neuropathies are rare, usually present in small ethnic groups, and named collectively CMT4 (see Table C22-2). These disorders may present in infancy and childhood with delayed motor milestones, severe neuropathies, and areflexia. Some patients become wheelchair bound by adulthood.

Electrodiagnosis

Electrodiagnostic (EDX) examination provides important information for the clinician suspecting a diffuse peripheral polyneuropathy or hereditary neuropathy.

In dying-back axonal peripheral polyneuropathy, the amplitudes of the CMAPs are diminished with stimulation at any site along the nerve without conduction blocks or significant temporal dispersion; however, the conduction velocities are normal or only slightly reduced (values usually are more than 80% of the lower limits of normal). By contrast, slowing of conduction velocities is pronounced in demyelinating polyneuropathy; values usually are less than 60% of the lower limits of normal, and there is relative preservation of CMAP amplitudes. When evoked, the sensory distal latencies and conduction velocities parallel the motor latencies and velocities. Conduction velocity values of the sural sensory nerve are less than 60% of the lower limits of normal in HMSN I, and are either normal or greater than 80% of the lower limits of normal in HMSN II.

Table C22-5 Electrophysiologic Characteristics of Demyelinating Polyneuropathy

Inherited (e.g., CMT1) Acquired (e.g., CIDP)
Diffuse slowing Multifocal slowing
Symmetrical slowing Asymmetrical slowing
No conduction block Frequent conduction blocks
Slight temporal dispersion Prominent temporal dispersion

CIDP = chronic inflammatory demyelinating polyneuropathy; CMT1 = Charcot-Marie-Tooth disease 1.

In summary, hereditary demyelinating neuropathy are characterized by diffuse, uniform, and symmetrical slowing, without conduction block or temporal dispersion. Common causes of hereditary demyelinating peripheral neuropathy with uniform slowing are shown in Table C22-6.

4. The distinction between the major subtypes of HMSN (CMT) may be guided on the basis of motor conduction velocities, since the clinical features of these disorders are similar enough that it often is difficult to distinguish between them without the aid of electrodiagnosis. This distinction helps tailoring the ever increasing number of genetic testing needed. In many cases of HMSN, the lower extremities are involved severely leading to absent or very low amplitude CMAPs and difficult to interpret conduction velocity values. In most cases, the upper extremity nerves are less severely affected, and their velocities, particularly the median and ulnar motor conduction velocities in the forearms, have proven to be very useful in guiding the clinician to the accurate genetic diagnosis of patients with CMT (Figure C22-4).

Table C22-6 Hereditary Demyelinating Peripheral Neuropathy Associated With Prominent and Uniform Slowing of Conduction Velocities

* Often associated with multifocal slowing and/or conduction block at common entrapment sites.

In general, needle EMG in patients with CMT shows no specific abnormalities; results are similar in both types of the disease. Because of the slow tempo of the disease, needle EMG often reveals signs of chronic partial denervation with reinnervation. Long-duration, high-amplitude MUAPs are present bilaterally, and there is reduced recruitment of MUAPs, particularly in the distal muscles of the lower and upper limbs. Fibrillation and, less commonly, fasciculation potentials are relatively inconspicuous and are identified mainly in distal muscles. Although fibrillation potentials are more common in CMT2 (neuronal form) than CMT1 (demyelinating form), this finding does not allow differentiation of these two disorders.